share_log

Morgan Stanley Maintains Equal-Weight on Amicus Therapeutics, Lowers Price Target to $14

Morgan Stanley Maintains Equal-Weight on Amicus Therapeutics, Lowers Price Target to $14

摩根士丹利维持对Amicus Therapeutics的同等权重,将目标股价下调至14美元
Benzinga ·  2023/10/10 11:17

Morgan Stanley analyst Andrew Galler maintains Amicus Therapeutics (NASDAQ:FOLD) with a Equal-Weight and lowers the price target from $15 to $14.

摩根士丹利分析师安德鲁·加勒坚持认为,之友治疗公司(纳斯达克:折叠)的权重相等,并将目标价从15美元下调至14美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发